Clinical Trials in Philadelphia

Showing 8321-8340 of 15,860 trials

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

NCT02808442

This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia

Institut de Recherches Internationales Servier13 participantsStarted Jun 2016

Los Angeles, California, United States • Philadelphia, Pennsylvania, United States • Dallas, Texas, United States +3 more locations

COMPLETEDPhase 1< 1 mile

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)45 participantsStarted Dec 2017

New York, New York, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 4< 1 mile

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Relapsing Multiple Sclerosis

Novartis Pharmaceuticals382 participantsStarted Sep 2017

Birmingham, Alabama, United States • Cullman, Alabama, United States • Tucson, Arizona, United States +63 more locations

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Find Trials by Condition in Philadelphia

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

A Study of ALKS 3831 in Adults With Schizophrenia

A Trial to Evaluate Medically Tailored Meals With Patients With Heart Failure

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Diagnostic Validation of Drug-Induced Sleep Endoscopy (DISE)

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

Fenestrated AAA Endovascular Graft Post-Approval Study

NSABP Biospecimen Discovery Project

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19